Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	2/9/2019 2:05:46 PM
	Read Replies (2) of 3557

RE: anti-CTLA4 (REGN4659) + anti-PD1 (Cemiplimab) in PD1/PDL1 experienced 2L /3L NSCLC P1/2 trial: Detailed description of the trial: worldwide.espacenet.com (page 82-92 of the W-PA) Tidbits: 350 and 1050 mg/Q3W cemiplimab dose will be used, 25/75/250mg/Q3W, Q6W, Q12W dose of REGN4659 will be tested escalation phase, in expansion cohorts, PD1/PDL1 experinced NSCLC will be tested. So, Idea of the anti-CTLA4 development is primarily (at this point) for experienced (anti-PD1) NSCLC with INCREASED Cemiplimab dose (1050 mg/3QW) and with assistance of the tolerance breaker, anti-CTLA4. And SNY did not like this idea????? While REGN think they have REAL SHOT!!!????

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next